However, it is important to consider that the perpetual caveat of clinical trials is the use of metastatic and generally heavily pre-treated cancer patients in typically small cohorts, often with little stratification based on the underlying disease biology (for example, based on elevated TGFβ2 or Slug expression, as alluded to in this study). Here, TGFB2 is linked to cancer.